Home › NDC Lookup › RxCUI directory › RxCUI 1539251

30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler — RxCUI 1539251

RxNorm drug concept · Semantic clinical drug
RxCUI 1539251 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1539251
Official name30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asumeclidinium 62.5 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA products mapped2
Package NDCs mapped3
Reported Medicaid activity (SDUD)137,953 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Umeclidinium Oral Inhalation: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No, this is not a rescue inhaler. Umeclidinium Ellipta is a maintenance inhaler, which means you take it once every day on a regular schedule to help keep your airways open and pre...
  • What exactly is this inhaler for — is it the one I use when I can't breathe?
  • Take one inhalation through the Ellipta device by mouth, once a day, at the same time each day — morning works well for most people. Never use it more than once in 24 hours. The de...
  • Most people tolerate this inhaler well. The most common side effects are things like a stuffy or runny nose, a sore throat, upper respiratory infections, cough, and joint pain. Mor...
📖 Read our full Umeclidinium Oral Inhalation guide →

🕸️ Concept Web — How 30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powd... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler RxCUI 1539251

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Umeclidinium 1487514
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Incruse 1539881
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Umeclidinium Dry Powder Inhaler 1539250
    • Umeclidinium Inhalant Product 1539249
    • Umeclidinium Dry Powder Inhaler [Incruse] 1539883
    • Incruse Inhalant Product 1539884
    • Dry Powder Inhaler 744995
    • Inhalant Product 1151123
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Umeclidinium 0.0625 MG/ACTUAT SCDC · 1487515
  • Umeclidinium Dry Powder Inhaler SCDF · 1539250
  • Umeclidinium Inhalant Product SCDG · 1539249

Brand-Name Concepts

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 1539251 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00173-0873-06 1 TRAY in 1 CARTON (0173-0873-06) / 1 INHALER in 1 TRAY / 7... Incruse Ellipta GlaxoSmithKline LLC 2014-04-30
00173-0873-10 1 TRAY in 1 CARTON (0173-0873-10) / 1 INHALER in 1 TRAY / 3... Incruse Ellipta GlaxoSmithKline LLC 2014-04-30
66993-0189-97 1 TRAY in 1 CARTON (66993-189-97) / 1 INHALER in 1 TRAY / 3... Umeclidinium Ellipta Prasco Laboratories 2026-04-06
Observed labelers: GlaxoSmithKline LLC (2) · Prasco Laboratories (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$10.2761
Range $7.4477–$11.2959 · middle 50% $8.8619–$10.7860 · 3 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.